Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/22561
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPliaka, V.en
dc.contributor.authorAchilleos, C.en
dc.contributor.authorKyriakopoulou, Z.en
dc.contributor.authorTsakogiannis, D.en
dc.contributor.authorRuether, I. G.en
dc.contributor.authorGartzonica, C.en
dc.contributor.authorLevidiotou-Stefanou, S.en
dc.contributor.authorMarkoulatos, P.en
dc.date.accessioned2015-11-24T19:25:02Z-
dc.date.available2015-11-24T19:25:02Z-
dc.identifier.issn1873-2518-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/22561-
dc.rightsDefault Licence-
dc.subjectAdolescenten
dc.subjectAdulten
dc.subjectAntibodies, Neutralizing/*blooden
dc.subjectAntibodies, Viral/*blooden
dc.subjectAntigens, Viral/genetics/*immunologyen
dc.subjectChilden
dc.subjectChild, Preschoolen
dc.subjectGreeceen
dc.subjectHumansen
dc.subjectInfanten
dc.subjectMolecular Sequence Dataen
dc.subjectMutation, Missenseen
dc.subjectPoliomyelitis/immunology/*prevention & controlen
dc.subjectPoliovirus/genetics/*immunologyen
dc.subjectPoliovirus Vaccine, Oral/genetics/*immunologyen
dc.subjectRNA, Viral/geneticsen
dc.subjectSequence Analysis, DNAen
dc.subjectViral Proteins/genetics/immunologyen
dc.subjectYoung Adulten
dc.titleDetermination of antigenic properties of vaccine derived poliovirus strainsen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1016/j.vaccine.2010.10.028-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/20974307-
heal.identifier.secondaryhttp://ac.els-cdn.com/S0264410X10014970/1-s2.0-S0264410X10014970-main.pdf?_tid=6674ced5fd70965bf735f7b8602a96b5&acdnat=1332826932_bd7df9b774614bdbebf2481003bf1199-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2010-
heal.abstractIn this study, the immunity level of the southern Greek population in the 1-10-year, 11-20-year, 21-30-year and 31-40-year age groups with regard to Sabin vaccine strains and a collection of 11 recombinant and three non-recombinant poliovirus vaccine strains was determined. The results showed the lowest neutralization titre in the 21-30-year-age group against poliovirus type 3. Moreover, the capsid coding region of OPV (oral poliovirus vaccine) derivatives was sequenced in order to identify mutations that might lead to antigenic changes. In Sabin-1 derivatives a tendency of accumulation of mutations was observed in or near antigenic sites while in Sabin-2 and Sabin-3 derivatives in sites known to be involved in restoring neurovirulence or eliminating their temperature-sensitive phenotype. It was concluded that the combination of mutations in the capsid coding region and not the number of specific mutations in antigenic sites determines the antigenic properties of OPV derivatives and their reactivity with human sera.en
heal.journalNameVaccineen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
File Description SizeFormat 
Pliaka-2010-Determination of ant.pdf214.08 kBAdobe PDFView/Open    Request a copy


This item is licensed under a Creative Commons License Creative Commons